TICKERNERD
Menu
OTLKOTLKHealthcare · Biotechnology

OTLK Stock Forecast: Outlook Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$0.61
−5.87% on the day

The 4 Wall Street analysts covering Outlook Therapeutics, Inc. hold a median 12-month price target of $4 — +556.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$157.1M
Ticker Nerd rank
4 / 100
Median analyst target
$4.00
Analysts covering
4
Revenue$127K
Operating income−$14.0M
Net income−$4.5M
Free cash flow−$7.8M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.4%
1M
−56.7%
YTD
−61.5%
1Y
−77.3%
From 52W high
−79.5%
From 52W low
+207.6%
$0.20
$2.97
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OTLK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Outlook Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
71
Revisions
51
Momentum
25
Volatility
20
Growth
8
Accruals
8
Value
5
Quality
4
Issuance
1

Size (71): Smaller than most of the companies we track.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OTLK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OTLK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26OTLKHigh $10.00Median $4.00Low $1.60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $1.60Median $4.00High $10.00

The green dot is the last close — the median target sits +556.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026BTIGReiteratesBuy$4.00
27 July 2026BTIGUpgradeBuy—
27 July 2026BTIGUpgradeBuy$4.00
27 July 2026HC Wainwright & Co.MaintainsNeutral—
27 July 2026HC Wainwright & Co.MaintainsNeutral$0.50 → $1.60
11 June 2026Ascendiant CapitalMaintainsBuy$6.00 → $10
11 June 2026Ascendiant CapitalMaintainsBuy—
18 May 2026BTIGDowngradeNeutral—
11 Mar 2026Ascendiant CapitalMaintainsBuy—
18 Feb 2026Chardan CapitalMaintainsNeutral—
18 Feb 2026HC Wainwright & Co.ReiteratesNeutral—
5 Jan 2026Chardan CapitalMaintainsNeutral—
2 Jan 2026HC Wainwright & Co.MaintainsNeutral—
22 Dec 2025Ascendiant CapitalMaintainsBuy—
30 Sept 2025HC Wainwright & Co.ReiteratesNeutral—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
29 Aug 2025GuggenheimDowngradeNeutral—
29 Aug 2025HC Wainwright & Co.DowngradeNeutral—
28 Aug 2025Chardan CapitalMaintainsNeutral—
15 Aug 2025Chardan CapitalMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OTLK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OTLK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Outlook Therapeutics, Inc. returned −77.3% against +19.6% for the S&P 500, dividends included.

OTLK vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26OTLKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OTLK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Outlook Therapeutics, Inc. (OTLK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.6×

Cheaper than 71% of US stocks

Price / sales
−135.0×

Cheaper than 99% of US stocks

Price / book
−1.8×

Cheaper than 95% of US stocks

EV / EBITDA
−3.0×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−99.4%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
−17.2%

Higher than 3% of US stocks

Operating margin
−124255.3%

Higher than 1% of US stocks

Net margin
4.0%

Higher than 57% of US stocks

Returns & dividend
Return on equity
193.9%

Higher than 98% of US stocks

Return on assets
−143.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Outlook Therapeutics, Inc. (OTLK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Outlook Therapeutics, Inc. has a market value of $157.1M and an enterprise value of $164.7M.

  • Revenue in the twelve months to 31 Mar 2026: $333K. The latest quarter shrank 99.4% year on year.

  • Net income over the same four quarters: −$61.0M, a −18297.5% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$47.0M.

  • Shares outstanding: 104.6M.

  • Trailing P/E: 0.6×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Outlook Therapeutics, Inc. employs 17 people — $20K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

OTLK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OTLKOutlook Therapeutics, Inc.$157.1M
4
OKUROnKure Therapeutics, Inc.$159.1M
55
MENSJyong Biotech Ltd.$161.8M
3
TNYATenaya Therapeutics, Inc.$151.0M
39
UNCYUnicycive Therapeutics, Inc.$150.3M
35
NRXPNRX Pharmaceuticals, Inc.$149.3M
20
CNTBConnect Biopharma Holdings Ltd.$148.6M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Outlook Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OTLK news & analysis

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Zacks Investment Research · 17 Aug 2026neutral

In its Q3 earnings call, Outlook Therapeutics outlined its U.S. LYTENAVA launch plan, targeting a year-end 2026 launch with $50M-$75M in first-year net revenues. The company tied the expected sales ramp to reimbursement dynamics.

Why it matters — For an OTLK watcher, this provides the company's own timing and revenue expectations for the LYTENAVA U.S. commercial launch, a key near-term catalyst for the stock.

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the earnings call transcript for Outlook Therapeutics, Inc. covering its third quarter of fiscal 2026. The item presents the transcript of the company's Q3 2026 earnings call.

Why it matters — A watcher of OTLK would be interested in the full transcript of the company's Q3 2026 earnings call for details on its financial results and operational updates.

Oncobiologics Q3 Earnings Call Highlights

MarketBeat · 14 Aug 2026positive

Outlook Therapeutics (OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the FDA approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration in the United States.

Why it matters — OTLK watchers would care because this marks a significant regulatory milestone enabling commercial readiness for its flagship ophthalmic product LYTENAVA in the U.S. market.

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Zacks Investment Research · 14 Aug 2026neutral

Outlook Therapeutics reported a Q3 loss of $0.09 per share, in line with the Zacks Consensus Estimate and an improvement from the $0.44 per share loss a year earlier. Revenue fell short of estimates.

Why it matters — The narrower quarterly loss and in-line results give OTLK watchers a read on the company's recent financial performance against analyst expectations.

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

GlobeNewsWire · 14 Aug 2026positive

Outlook Therapeutics reported its third quarter fiscal year 2026 financial results and provided a business update highlighting the FDA approval of LYTENAVA. The company notes that LYTENAVA is the only FDA-approved ophthalmic bevacizumab and addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used.

Why it matters — This update matters to OTLK watchers because FDA approval of LYTENAVA represents a major regulatory milestone and potential commercial opportunity for the company's lead ophthalmic product in the wet AMD market.

FAQ

Frequently asked questions about OTLK stock

What is the OTLK stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Outlook Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $1.6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OTLK stock a buy right now?

Of the 4 analysts covering Outlook Therapeutics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outlook Therapeutics, Inc. 4 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OTLK?

As at 22 Aug 2026, Outlook Therapeutics, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).

Will OTLK stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +556.8% from the last close, and Ticker Nerd's factor model ranks Outlook Therapeutics, Inc. 4 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OTLK stock forecast for 2030?

No analyst covering Outlook Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OTLK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $10 over the next 12 months.

How has OTLK stock performed over the past year?

Outlook Therapeutics, Inc. returned -77.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Outlook Therapeutics, Inc. do?

Outlook Therapeutics Inc. is a late clinical-stage biopharmaceutical company specializing in ophthalmology.

What is the latest news on OTLK?

The most recent item we track (Zacks Investment Research, 17 Aug 2026): "OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp". In its Q3 earnings call, Outlook Therapeutics outlined its U.S. LYTENAVA launch plan, targeting a year-end 2026 launch with $50M-$75M in first-year net revenues. The company tied the expected sales ramp to reimbursement dynamics.

Company

About Outlook Therapeutics, Inc.

Outlook Therapeutics Inc. is a late clinical-stage biopharmaceutical company specializing in ophthalmology. The company is focused on developing and commercializing ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab designed for the treatment of retinal diseases, particularly neovascular or “wet” age-related macular degeneration (wet AMD). Its lead product candidate seeks to provide a standardized, rigorously tested alternative to repackaged intravenous bevacizumab commonly used off-label in retinal care today. By concentrating on retina specialists and eye-care providers, Outlook Therapeutics aims to address important needs in dosing consistency, sterility, and regulatory oversight for anti-VEGF therapies used in vision-threatening conditions. Headquartered in Iselin, New Jersey, and founded in the United States, the company operates within the broader biotechnology and pharmaceutical markets, with a clear emphasis on improving treatment options for patients with serious retinal disorders.

CEO Mr. Robert Charles Jahr · 17 employees · United States · https://outlooktherapeutics.com